CD19 and acute lymphoblastic leukemia: In mouse xenograft models of ALL and lymphoma, dasatinib potently ablated the signaling of CD19-targeting CAR T cells, leading to the suppression of cytotoxicity, cytokine secretion, and proliferation [99,100].